| 摘要 |
The present invention relates to a transformed T-cell for T-cell therapy, and a composition including same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the removal of an intracellular signaling domain of CTLA4 or PD1, which is a surface immune tolerance-induced receptor for a T-cell surface, and by the transfection of a gene for coding a CTLA4-CD28 chimera protein or PD1-CD28 chimera protein to which an intracellular activation transduction domain of CD28, which is T-cell activation surface protein, is bound. The T-cell, to which the gene for coding the CTLA4-CD28 chimera protein or PD1-CD28 chimera protein is transected, can solve the problem of impeded therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction of CD28 to induce the activation of T-cells. Also, the activation of CTLA4 or PD1 is inhibited only in cancer cell-specified T-cells, so that it is possible to minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation which may occur in the case where a non-specific CTLA4 or PD1 antagonist is used - for example, a typical anti-CTLA4 antibody. |
